Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HeartWare Touts Early Success In U.S. Launch Of HVAD

This article was originally published in The Gray Sheet

Executive Summary

HeartWare sold 134 HVAD ventricular assist systems in the U.S. following FDA approval in November and continues to rapidly add more centers to its customer base.

You may also be interested in...



HeartWare HVAD Meets Primary Endpoint For Destination Therapy

Results of the 446-patient trial presented at the International Society for Heart and Lung Transplantation Annual Meeting show non-inferiority of the HVAD to FDA-approved ventricular assist devices in destination therapy patients.

HeartWare Adds Synergy Circulatory Support System With $30 Mil. CircuLite Buy

The acquisition could significantly expand the targeted market base for HeartWare, but first the company will need to re-launch CircuLite’s Synergy in Europe, which experiences a design problem the first time around.

Proposed NCD May Give Thoratec An Edge Over HeartWare

Related Content

Related Companies

UsernamePublicRestriction

Register

MT032768

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel